NCT01486563

Brief Summary

The purpose of this project is to investigate if hydroxyethyl starch (HES) is potential nephrotoxic and examine the effects on the circulation and kidneys during administration of HES during surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at below P25 for phase_4 prostate-cancer

Timeline
Completed

Started Jan 2012

Shorter than P25 for phase_4 prostate-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 4, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 6, 2011

Completed
26 days until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

September 17, 2013

Status Verified

September 1, 2013

Enrollment Period

1.4 years

First QC Date

December 4, 2011

Last Update Submit

September 16, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • u-NGAL

    The main objective for the trial (only patients undergoing elective radical prostatectomy) is to measure the effect of hydroxyethyl starch on u-NGAL, which is a biomarker of nephrotoxicity

    2-4 hours

Secondary Outcomes (4)

  • u-Kim 1, u- FABP

    2-4 hours

  • FENa, u-ENaCβ, CH2O, u-AQP2,u-NCC, u-NK2CC

    2-4 hours

  • PRC, p-Ang-II, p -Aldo, p-ANP,P-GDP, p-AVP, p-Endot

    2-4 hours

  • SBP, DBP, heartrate

    2-4 hours

Study Arms (2)

Voluven (Hydroxyethyl starch 130/0,4)

ACTIVE COMPARATOR

Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)

Drug: Voluven (Hydroxyethyl starch 130/0,4)

Sodium Chloride 9 mg/ml

PLACEBO COMPARATOR

Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)

Drug: Sodium Chloride 9 mg/ml

Interventions

7,5 ml/kg in the first hour and then 5 ml/kg

Also known as: Voluven, Venofundin, Hydroxyethyl starch
Voluven (Hydroxyethyl starch 130/0,4)

7,5 ml/kg in the first hour and then 5 ml/kg

Also known as: Istone saline solution
Sodium Chloride 9 mg/ml

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 18 years
  • Males
  • Indication for radical prostatectomy

You may not qualify if:

  • Blood donation within the last month
  • Lack of wish to participate
  • eGFR\< 15ml/min

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medicinsk forskningsafsnit, Regionshospitalet Holstebro

Holstebro, 7500, Denmark

Location

Related Publications (1)

  • Kancir ASP, Johansen JK, Ekeloef NP, Pedersen EB. The effect of 6% hydroxyethyl starch 130/0.4 on renal function, arterial blood pressure, and vasoactive hormones during radical prostatectomy: a randomized controlled trial. Anesth Analg. 2015 Mar;120(3):608-618. doi: 10.1213/ANE.0000000000000596.

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

HES 130-0.4Hydroxyethyl Starch DerivativesSodium Chloride

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

StarchDietary CarbohydratesCarbohydratesGlucansPolysaccharidesChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Anne Sophie P. Kancir, MD PhD

    Holstebro Regional Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 4, 2011

First Posted

December 6, 2011

Study Start

January 1, 2012

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

September 17, 2013

Record last verified: 2013-09

Locations